Vanguard Global Advisers
XERS icon

Vanguard Global Advisers’s Xeris Biopharma Holdings XERS Stock Holding History

Vanguard Global Advisers’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$488K Sell
61,623
-14,888
-19% -$95.1K ﹤0.01% 2115
2026
Q1 		$444K Buy
+76,511
New +$507K ﹤0.01% 2100

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Global Advisers's XERS Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Xeris Biopharma Holdings (XERS) stake by 19% in Q2 2026, selling an estimated $95.1K and leaving 61,623 shares worth $488K. The position accounts for ﹤0.01% of the portfolio, ranked #2115.

Vanguard Global Advisers first reported a position in XERS in Q1 2026 and has held it in 2 quarters since. 236 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Vanguard Global Advisers held 61,623 shares of Xeris Biopharma Holdings worth $488K as of Q2 2026.
  • Vanguard Global Advisers sold 14,888 Xeris Biopharma Holdings shares in Q2 2026, an estimated $95.1K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2115 holding.
  • Vanguard Global Advisers first reported a position in Xeris Biopharma Holdings in Q1 2026 and has held it in 2 quarters since.
  • 236 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.